

CURRICULUM VITAE

PERSONAL



NAME(姓名，含英譯)

江珠影 JIANG, JU YING

PROFESSIONAL APPOINTMENT (現職，含英譯)

亞東紀念醫院臨床試驗中心主任 Chief, Clinical Trial Center of Far Eastern Memorial Hospital, New Taipei City

亞東紀念醫院新陳代謝科主治醫師 Attending physician of Division of Endocrinology & Metabolism, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City

遠東聯合診所內科部兼任主治醫師 Attending physician of Department of Internal Medicine, Far Eastern Polyclinic, Taipei

板橋翰生聯合診所兼任主治醫師 Attending physician of Han Shen Clinic, Banciao

銘傳大學醫療資訊與管理學系兼任講師 Lecturer of Department of Healthcare Information and Management, Ming Chuan University

教育部部定講師 Lecturer, Ministry of Education

EDUCATION(學歷)

國立台灣大學醫學系學士 Department of Medicine, College of Medicine, National Taiwan University, Taiwan

國立台灣大學衛生政策與管理研究所碩士 Graduate Institute of Health Policy and Management, Public Health Division, College of Public Health, National Taiwan University, Taiwan

WORKING EXPERIENCE (經歷)

國立台灣大學附設醫院內科部住院醫師 Resident of National Taiwan University Hospital, Taiwan

國立台灣大學附設醫院內科部總住院醫師 Chief resident of National Taiwan University Hospital, Taiwan

國立台灣大學附設醫院內科部分泌暨新陳代謝科研究員 Fellowship of Endocrinology &

Metabolism of National Taiwan University, Taiwan

MAJOR RESEARCH AREA(研究領域)

Diabetes, dyslipidemia, endocrine disorder

PUBLICATION(In the nearest 5 years)(發表、出版物)

1. Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, McGill JB, Rosas SE, Joseph A, Gebel M, Roberts L, Scheerer MF, Bakris GL, Agarwal R; FIDELIO-DKD and FIGARO-DKD Investigators. (**Jiang JY**) Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes Care 2022; 45(12):2991-2998
2. **Jiang JY**, Hsu CX, Yen SH. Factors affecting long-term survival of non-small-cell lung cancer patients with concomitant type 2 diabetes mellitus. Thoracic Cancer 2023; 14(1): 108-109
3. Lu JY, Ou HY, Wu CZ, Yang CY, **Jiang JY**, Lu CH, Jiang YD, Chang TJ, Chang YC, Hsieh ML, Wu WC, Li HY, Du YF, Lin CH, Hung HC, Tien KJ, Yeh NC, Lee SY, Yu HI, Chuang LM. A randomized trial on the effect of transcutaneous electrical nerve stimulator on glycemic control in patients with type 2 diabetes. Sci Rep. 2023 Feb 15;13(1):2662

GLP-1 受體促效劑的個體化治療策略：基於患者需求的最佳選擇

Personalized Therapeutic Strategies for GLP-1 Receptor Agonists: Optimizing Selection Based on Patient Needs

江珠影

亞東紀念醫院 新陳代謝科

GLP-1-受體促效劑 (GLP-1 RAs) 已成為第二型糖尿病治療中的重要藥物選擇，不僅有助於控制血糖，還具備減重與器官保護等附加益處。然而，由於患者在疾病嚴重程度、併發症風險、生活型態與治療目標等方面存在高度異質性，實施個體化治療策略尤為關鍵。

根據目前的臨床指引與實證研究，應根據患者的主要需求——如是否優先降低心血管風險、減重或提升治療依從性——選擇合適的 GLP-1 RA 種類與劑型。此外，治療應考量藥物副作用、注射頻率、保險給付與患者偏好，以提升整體療效與生活品質。未來個體化治療也將結合基因資訊與數位健康工具，強化精準醫療的應用。

本課程將探討 GLP-1 RA 以病患為中心的個體化治療策略應，結合臨床證據與多面向評估，以實現更佳的治療成效與病患滿意度。